by Dr Ken Gillman | Last updated Feb 23, 2020 | Published on Feb 23, 2020 | General Pharmacology
Search for: General Pharmacology1. Reasons to choose a TCA 2. Understanding Receptor Affinity Data 3. The Vesicular Monoamine Transporter 4. QT Assessment and Psychotropics 5. The placebo response: Phenomenon or phantasm? 6. Why Most New Antidepressants Are...
by Dr Ken Gillman | Published on Jan 26, 2020 | General Pharmacology
Search for: General Pharmacology1. Reasons for choosing a TCA before an SSRI 2. Understanding Receptor Affinity Data 3. The Vesicular Monoamine Transporter (VMAT2) 4. QT Interval Assessment, Psychotropic Drugs and the Influence of Product Information 5. The placebo...
by Dr Ken Gillman | Last updated Oct 17, 2021 | Published on Jan 12, 2020 | General Pharmacology
Search for: Recent Commentaries Menu International MAOI expert group: Editorial and recommendationsStepped trials: Magnifying methodological muddles — the supernatant effectThe risk of harm from acute tyramine-induced hypertension: how significant?Advising patients...
by Dr Ken Gillman | Last updated Oct 17, 2021 | Published on Nov 13, 2010 | General Pharmacology
Search for: GENERAL PHARMACOLOGY MENU 1. Reasons to choose a TCA 2. Understanding Receptor Affinity Data 3. The Vesicular Monoamine Transporter 4. QT Assessment and Psychotropics 5. The placebo response: Phenomenon or phantasm? 6. Why Most New Antidepressants Are...
